A Phase 2 Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Silevertinib, an Oral EGFR Inhibitor, in Combination With Temozolomide in Patients With Newly Diagnosed Glioblastoma With Unmethylated MGMT Promoter and EGFRvIII

This study is testing a new way to treat a type of aggressive brain tumor called glioblastoma. Researchers want to see if adding a new drug called silevertinib to standard chemotherapy helps patients live longer and keeps the tumor from growing.

This study is for adults who have been recently diagnosed with glioblastoma and have already completed surgery, radiation, and initial chemotherapy. Participants must have specific genetic markers in their tumor cells and their cancer must not have spread or worsened after initial treatment.

You will be given either the new drug combination (silevertinib plus chemotherapy) or the standard chemotherapy alone to compare the results. Throughout the study, your medical team will closely monitor you to check how well the treatment is working and manage any side effects.

The study is currently recruiting patients at medical centers in Springdale, Arkansas; Los Angeles, California; and New Haven, Connecticut. You can talk to your doctor to see if one of these locations is an option for you.